StockDuty ← Dashboard Sep 09, 2026 11:36 AM ET
SignalCorporate

Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery

Acquisition targets metabolic disease drug discovery, a high-value therapeutic area with immediate R&D relevance.

Acquisition targets metabolic disease drug discovery, a high-value therapeutic area with immediate R&D relevance.
Acquisition targets metabolic disease drug discovery, a high-value therapeutic area with immediate R&D relevance. — impact context not separately stored; see What changed.
Sources